MX2010001092A - Composicion farmaceutica liquida estable basada en trazodona. - Google Patents

Composicion farmaceutica liquida estable basada en trazodona.

Info

Publication number
MX2010001092A
MX2010001092A MX2010001092A MX2010001092A MX2010001092A MX 2010001092 A MX2010001092 A MX 2010001092A MX 2010001092 A MX2010001092 A MX 2010001092A MX 2010001092 A MX2010001092 A MX 2010001092A MX 2010001092 A MX2010001092 A MX 2010001092A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
trazodone
stable liquid
liquid pharmaceutical
composition based
Prior art date
Application number
MX2010001092A
Other languages
English (en)
Inventor
Francesca Mariotti
Lorella Ragni
Mauro Valenti
Marcello Marchetti
Paolo Scarpetti
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of MX2010001092A publication Critical patent/MX2010001092A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

Se describe una composición farmacéutica líquida estable que comprende una solución acuosa de una sal farmacéuticamente aceptable de adición de ácido de trazodona, caracterizada en que la composición farmacéutica tiene un valor de pH entre 5.0 y 6.0, y comprende por lo menos dos cosolventes seleccionados del grupo que comprende glicoles y poliglicoles.
MX2010001092A 2007-07-31 2008-07-22 Composicion farmaceutica liquida estable basada en trazodona. MX2010001092A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001573A ITMI20071573A1 (it) 2007-07-31 2007-07-31 Composizione farmaceutica liquida stabile a base di trazodone
PCT/EP2008/059605 WO2009016069A2 (en) 2007-07-31 2008-07-22 Stable liquid pharmaceutical composition based on trazodone

Publications (1)

Publication Number Publication Date
MX2010001092A true MX2010001092A (es) 2010-03-01

Family

ID=38858941

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001092A MX2010001092A (es) 2007-07-31 2008-07-22 Composicion farmaceutica liquida estable basada en trazodona.

Country Status (25)

Country Link
US (1) US10292931B2 (es)
EP (2) EP2182920B1 (es)
JP (1) JP5426548B2 (es)
KR (1) KR101493370B1 (es)
CN (1) CN101784257B (es)
AR (1) AR068327A1 (es)
AU (1) AU2008281858B2 (es)
BR (1) BRPI0814658A2 (es)
CA (1) CA2692975C (es)
CY (1) CY1116189T1 (es)
DK (2) DK2182920T3 (es)
EA (1) EA016822B1 (es)
ES (2) ES2399569T3 (es)
GE (1) GEP20125525B (es)
HK (2) HK1138207A1 (es)
HR (1) HRP20150349T1 (es)
IL (1) IL203167A (es)
IT (1) ITMI20071573A1 (es)
MX (1) MX2010001092A (es)
PL (2) PL2494955T3 (es)
PT (2) PT2182920E (es)
SG (1) SG183659A1 (es)
SI (2) SI2182920T1 (es)
UA (1) UA102376C2 (es)
WO (1) WO2009016069A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20071603A1 (it) 2007-08-03 2009-02-04 Acraf Trazodone e trazodone cloridrato in forma purificata
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
RU2706700C1 (ru) * 2019-09-24 2019-11-20 Общество с ограниченной ответственностью "Научно-производственная компания "СКиФФ" Фармацевтическая композиция для коррекции поведения кошек и собак в стрессовых ситуациях
WO2021058810A1 (en) 2019-09-26 2021-04-01 Angelini S.P.A. Pediatric trazodone compositions and method of treatment thereof
CN111568861A (zh) * 2020-05-25 2020-08-25 河北科星药业有限公司 畜禽用盐酸溴己新口服液及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154832A (en) * 1974-08-26 1979-05-15 Bruno Silvestrini Novel treatment for acute organic cerebral syndromes (strokes)
IT1233412B (it) * 1987-12-02 1992-03-30 Acraf Uso del trazodone
BR9912395A (pt) * 1998-07-24 2001-10-16 Seo Hong Yoo Preparação de formas de dosagem de solução clara aquosa com ácidos biliares
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
ITMI20071603A1 (it) 2007-08-03 2009-02-04 Acraf Trazodone e trazodone cloridrato in forma purificata

Also Published As

Publication number Publication date
US10292931B2 (en) 2019-05-21
SI2182920T1 (sl) 2013-04-30
US20100256159A1 (en) 2010-10-07
IL203167A (en) 2017-08-31
PL2494955T3 (pl) 2015-06-30
JP5426548B2 (ja) 2014-02-26
WO2009016069A4 (en) 2009-05-14
CA2692975A1 (en) 2009-02-05
DK2494955T3 (en) 2015-04-13
ITMI20071573A1 (it) 2009-02-01
EP2494955B1 (en) 2015-01-21
EP2494955A2 (en) 2012-09-05
JP2010534703A (ja) 2010-11-11
EP2494955A3 (en) 2012-10-03
GEP20125525B (en) 2012-05-25
DK2182920T3 (da) 2013-03-04
AU2008281858A1 (en) 2009-02-05
HK1138207A1 (en) 2010-08-20
PT2182920E (pt) 2013-03-07
EA201070194A1 (ru) 2010-06-30
UA102376C2 (ru) 2013-07-10
CN101784257A (zh) 2010-07-21
CN101784257B (zh) 2012-11-28
WO2009016069A3 (en) 2009-03-19
WO2009016069A2 (en) 2009-02-05
BRPI0814658A2 (pt) 2015-02-18
SG183659A1 (en) 2012-09-27
EP2182920B1 (en) 2012-12-26
EA016822B1 (ru) 2012-07-30
CA2692975C (en) 2016-01-12
PL2182920T3 (pl) 2013-05-31
ES2531241T3 (es) 2015-03-12
HRP20150349T1 (hr) 2015-05-22
KR20100038112A (ko) 2010-04-12
AR068327A1 (es) 2009-11-11
PT2494955E (pt) 2015-03-04
EP2182920A2 (en) 2010-05-12
ES2399569T3 (es) 2013-04-02
CY1116189T1 (el) 2017-02-08
HK1176280A1 (en) 2013-07-26
KR101493370B1 (ko) 2015-02-13
SI2494955T1 (sl) 2015-04-30
AU2008281858B2 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
WO2007089768A3 (en) 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
WO2007147160A3 (en) Aprepitant compositions
EP1995246A4 (en) NITROGENATED HETEROCYCLIC DERIVATIVE AND MEDICAMENT WITH DERIVATIVE ACTIVE SUBSTANCE
MY154909A (en) Novel thiophene derivatives
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
IL192948A0 (en) Novel pyridine derivatives
UA105078C2 (uk) Фармацевтична композиція, яка містить тетрагідрофолієву кислоту
HK1079207A1 (en) Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor
UA94065C2 (en) Dihydropseudoerythromycin derivatives
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
WO2007030361A3 (en) Benzimidazole thiophene compounds as plk inhibitors
WO2007016352A3 (en) Oral liquid losartan compositions
MY152885A (en) Medicament containing fluoroquinolones
CY1116189T1 (el) Σταθερη υγρη φαρμακευτικη συνθεση με βαση την τραζοδονη
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
MX2009003169A (es) Derivados de sulfonamida.
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
SG162766A1 (en) Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
MX2009007384A (es) Formulaciones que contienen ?-lactama con elevada estabilidad en disolucion acuosa.
MY146803A (en) Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors
WO2011036357A3 (fr) Formulation liquide, stable, prete a l'emploi de ketoprofene

Legal Events

Date Code Title Description
FG Grant or registration